Arcticzymes Technologies ASA
F:B4V
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Arcticzymes Technologies ASA
F:B4V
|
NO |
|
G
|
Gilead Sciences Inc
F:GIS
|
US |
|
Iovance Biotherapeutics Inc
NASDAQ:IOVA
|
US |
|
Goldman Sachs BDC Inc
NYSE:GSBD
|
US |
|
AAR Corp
NYSE:AIR
|
US |
|
Credit Agricole SA
MIL:1ACA
|
FR |
|
Koninklijke Philips NV
MIL:1PHIA
|
NL |
|
W
|
Walt Disney Co
XMUN:WDP
|
US |
|
B
|
Bank Mandiri (Persero) Tbk PT
XMUN:PQ9
|
ID |
|
Premium Group Co Ltd
TSE:7199
|
JP |
|
Naver Corp
KRX:035420
|
KR |
|
Centerspace
NYSE:CSR
|
US |
|
MGM Resorts International
NYSE:MGM
|
US |
Arcticzymes Technologies ASA
ArcticZymes Technologies makes specialized enzymes used in life science work, especially in molecular research, diagnostics, and the production of biological medicines. Its products help customers copy, cut, or remove DNA and RNA in lab workflows, which is important for tests, sample preparation, and certain manufacturing steps. The company sells these enzyme products rather than finished consumer goods, so it sits upstream in the biotech supply chain. Its main customers are biotechnology companies, diagnostics developers, research labs, and drug manufacturers that need reliable tools for handling nucleic acids. ArcticZymes earns money by selling enzyme products and related formulations that customers use in their own assays, kits, and production processes. In practice, it makes its business by turning specialized biological molecules into tools that other life science companies build into their products. What makes the business different is its focus on enzymes from cold-adapted organisms, which can be useful in workflows that need precise activity under controlled conditions. That gives the company a narrow but important role: it is not trying to make drugs or run labs itself, but to supply the technical ingredients that make those products and processes work. This makes ArcticZymes more of a specialist materials supplier for biotech and diagnostics than a broad healthcare company.
ArcticZymes Technologies makes specialized enzymes used in life science work, especially in molecular research, diagnostics, and the production of biological medicines. Its products help customers copy, cut, or remove DNA and RNA in lab workflows, which is important for tests, sample preparation, and certain manufacturing steps. The company sells these enzyme products rather than finished consumer goods, so it sits upstream in the biotech supply chain.
Its main customers are biotechnology companies, diagnostics developers, research labs, and drug manufacturers that need reliable tools for handling nucleic acids. ArcticZymes earns money by selling enzyme products and related formulations that customers use in their own assays, kits, and production processes. In practice, it makes its business by turning specialized biological molecules into tools that other life science companies build into their products.
What makes the business different is its focus on enzymes from cold-adapted organisms, which can be useful in workflows that need precise activity under controlled conditions. That gives the company a narrow but important role: it is not trying to make drugs or run labs itself, but to supply the technical ingredients that make those products and processes work. This makes ArcticZymes more of a specialist materials supplier for biotech and diagnostics than a broad healthcare company.
Revenue: ArcticZymes reported total revenue of NOK 35 million, up 41% year on year, or 50% on a constant-currency basis, with management calling Q1 the strongest first quarter on record excluding COVID.
Profitability: EBITDA turned positive at NOK 1.6 million, versus negative NOK 3.7 million a year ago, showing the benefit of operating leverage as sales grow.
Segment mix: Biomanufacturing posted just over NOK 15 million in revenue, while Molecular Tools reached NOK 16.6 million; both segments contributed to the better-than-usual quarter.
RNA push: The company won a European patent for its RNA restriction enzyme portfolio and said the first solutions in this area are targeted for late this year or early next year.
Commercial momentum: Management highlighted stronger demand from large CDMOs, improving diagnostics visibility, and 25 new paying customers in the quarter, while noting some concentration and regional phasing risks.
Balance sheet: Cash and short-term investments stood at NOK 264 million, with no interest-bearing debt and an equity ratio of about 94%.
